SystImmune, Inc. to Present New iza-bren (izalontamab brengitecan) Data in Extensive Stage Small Cell Lung Cancer at ELCC 2026
- Safety & efficacy of iza-bren, an EGFRxHER3 bispecific topoisomerase inhibitor- based antibody-drug conjugate (ADC) in combination with serplulimab (an anti-PD1 antibody), in treatment-naive patients with Extensive stage Small Cell Lung Cancer (ES-SCLC) will be presented
SI
systimmune; inc
via Mohavedailynews - Corroborated by 1 others
Updated 10h ago
Source Verification
Corroboration Score: 2This story was independently reported by 2 sources. Click any source to read the original article.
Comments
0 commentsBe respectful and constructive.
Loading comments...
Previous
Stop sleeping on mechanical keyboards when this top-rated pick just got a steep $200 discount
Next
